SCHEMBL23979952

SCHEMBL23979952

Cc1nc2ccc(NC(=O)COCc3ccccc3)cc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 4/20 0.51
▸ CRBN Q96SW2 4/20 0.51
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ PTPRC P08575 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ ACHE P22303 4/20 0.41
▸ BCHE P06276 3/20 0.41
▸ TNF P01375 1/20 0.40
▸ IL1B P01584 1/20 0.40
▸ IKZF3 Q9UKT9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655103 0.95 CRBN (0.57) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL16221478 0.80 DDB1 (0.46) DDB1CRBNSMN1; SMN2NPC1RAB9A
SCHEMBL18900415 0.79 CRBN (0.56) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL283716 0.79 CRBN (0.56) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL23979424 0.77 CRBN (0.62) DDB1CRBNKDM4EHSD17B10TNF
SCHEMBL23979951 0.77 ALDH1A1 (0.40) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL23979382 0.77 DDB1 (0.51) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL24113855 0.76 DDB1 (0.61) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL23979418 0.76 DDB1 (0.49) DDB1CRBNKDM4EMEN1KMT2A
SCHEMBL15943330 0.76 CRBN (0.60) DDB1CRBNKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 — — US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885KDM4E 732/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885KDM4E 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback